Pushing for a New Era in Cardiology: Matt Killeen, PhD

Commentary
Video

Matt Killeen, PhD, chief scientific officer at Renovacor, shares updates on the company's lead candidate, REN-001, an adeno-associated viral vector serotype 9-based gene therapy for the treatment of BAG3-associated dilated cardiomyopathy.

"Given the fact that today's therapies for heart failure and inherited heart diseases really just work around the edges, patients can quickly find themselves exhausting current treatment options and facing the prospect of procedures." —Matt Killeen, PhD, Chief Scientific Officer, Renovacor

As more and more patients become empowered to take control of their individual health, there is increasing emphasis on cardiac screening and genetic testing. One form of genetically driven heart failure, BAG3-associated dilated cardiomyopathy (DCM), has become an area of focus, as there are currently no commercially available targeted treatments.

Researchers at Renovacor are hoping to change that with REN-001, an adeno-associated viral (AAV) vector serotype 9-based gene therapy for the treatment of DCM.

Matt Killeen, PhD, chief scientific officer at Renovacor, joins CGTL to share updates on REN-001, which is in late stage preclinical development, and other candidates in the pipeline, as well as to shed some light on why the company chose to focus on this genetic form of heart disease.

Recent Videos
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.